Melbourne company Phosphagenics (ASX: POH) has announced the appointment of three new directors to its Board.
The new directors are Dr Greg Collier, Mr Peter Lankau and the Company’s recently appointed CEO, Dr Ross Murdoch.
Dr Greg Collier is currently the CEO of ASX listed company Invion, and has more than 20 years experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialisation.
Mr Peter Lankau served as the Chief Executive Officer of Endo Pharmaceuticals from 2005 to 2008, having been Chief Operating Officer from 2003 to 2005. From 2000 to 2003, he served as Senior Vice President of its US Business.
Endo has in recent years become one of the largest companies commercialising drugs to treat pain. Its product range includes Lidoderm (lidocaine), Percodan (oxycodone with asprin), Opana (oxymorphone) and Voltaren Gel (diclofenac).
In recent years, Mr Lankau has served on multiple company boards including Nautilus Neuroscience, which in 2013 divested assets including its oral diclofenac product to Depomed for over $50 million.
Dr Ross Murdoch has over 25 years’ experience in the global healthcare, pharmaceutical and biotech industries. He has held senior and executive positions with global pharmaceutical companies such as GlaxoSmithKline, Astra Zeneca and Shire Pharmaceuticals .
He has also worked for much smaller companies such as Prana Biotechnology where he was COO. His appointment to the board was a natural transition, having commenced as CEO of Phosphagenics in January 2015.
Lawrence Gozlan chairman of Phosphagenics said, “I am delighted to welcome the newly appointed directors to Phosphagenics’ board. The skill set of these directors will be invaluable in optimising commercial outcomes for Phosphagenics’ TPM platform technology. They are highly respected by their peers and their willingness to serve on the board is a strong endorsement of our technology.”